XML 60 R49.htm IDEA: XBRL DOCUMENT v3.25.1
Share-based Compensation - Stock Option Activity Under 2023 Incentive Award Plan (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Options, Weighted Average Exercise Price      
Share-based compensation expense $ 1.7 $ 1.6  
AEON Biopharma Inc 2023 Incentive Award Plan | Stock options      
Options, Number of Shares      
Outstanding, beginning of period 51,016    
Outstanding, end of period 51,016   51,016
Exercisable, end of period 18,280    
Options, Weighted Average Exercise Price      
Outstanding, beginning of period $ 242.14    
Outstanding, end of period 242.14   $ 242.14
Exercisable, end of period $ 78.93    
Weighted average fair value of options granted per share     $ 135.5
Weighted average remaining contractual life of options exercisable 9 years 2 months 12 days   9 years 6 months
Share-based compensation expense $ 0.6 $ 0.1  
Unrecognized compensation expense related to non-vested stock options $ 4.7   $ 5.3
Weighted-average remaining requisite service period for which unrecognized compensation expense 16 months   19 months